Modality
mRNA
MOA
SHP2i
Target
IL-23
Pathway
Ferroptosis
Huntington'sBCC
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
Nov 2017
→ Jun 2025
Phase 3Current
NCT08986784
992 pts·BCC
2021-09→2025-06·Completed
NCT06660320
756 pts·Huntington's
2017-11→2025-01·Active
1,748 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-111.2y agoPh3 Readout· Huntington's
2025-06-249mo agoPh3 Readout· BCC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P3
Active
P3
Complet…
Catalysts
Ph3 Readout
2025-01-11 · 1.2y ago
Huntington's
Ph3 Readout
2025-06-24 · 9mo ago
BCC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08986784 | Phase 3 | BCC | Completed | 992 | OS |
| NCT06660320 | Phase 3 | Huntington's | Active | 756 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 |